LAG3 and lung carcinoma: There are however, a number of alternative or complementary avenues for further exploration of combination treatments that may improve regime efficacy, including targeting TIM-3 and Lag-3, additional co-inhibitory receptors known to be clinically significant in lung cancer escape from immune control (41) or inhibition of TReg (42) and MDSC suppressive cells (43) within the developing TME.